Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.

Original languageEnglish
Pages (from-to)1824-1826
Number of pages3
JournalClinical Cancer Research
Volume18
Issue number7
DOIs
StatePublished - 1 Apr 2012

Fingerprint

Dive into the research topics of 'Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib'. Together they form a unique fingerprint.

Cite this